Icon PLC

Anne S. Renteria, MD, named site director of Perlmutter Cancer Center's Transplantation and Cellular Therapy Center at NYU Langone Hospital—Long Island. She will expand blood cancer programs and coordinate with various experts for comprehensive care. Dr. Renteria, a clinical associate professor, brings extensive leadership and research experience in hematologic malignancies and hematopoietic cell therapies.

Resonance Health acquired TrialsWest for A$8M, expanding into clinical trial operations. Outsourcing clinical trials enhances efficiency, cost-effectiveness, and regulatory compliance, benefiting companies by optimizing resources and focusing on core activities.

Resonance Health acquired TrialsWest for A$8M, expanding into clinical trials. The global Clinical Trial Outsourcing market was valued at USD 52.39B in 2023 and is projected to reach USD 111.01B by 2032, with a CAGR of 8.7%. Outsourcing offers cost-effectiveness, faster timelines, and regulatory compliance, but faces challenges like rising costs and undisclosed expenses.

Margaret Keegan, former operating partner at Linden Capital Partners, is now CEO of Precision Medicine Group, a specialized services provider in drug development and commercialization. Keegan aims to elevate Precision's profile, leveraging her extensive experience in the industry to guide the company from being a 'best-kept secret' to an industry leader. She highlights Precision's broad operations and expertise in precision medicine, emphasizing the importance of AI in transforming drug development and commercialization.

The clinical trial market, valued at USD 50.66M in 2023, is projected to reach USD 75.72M by 2032 with a CAGR of 5.91%. Factors driving growth include high R&D expenditure, rising disease prevalence, and demand for personalized medicine. Trends like decentralized trials and regulatory support from agencies like FDA and EMA are enhancing market efficiency. Key players include Sanofi SA, Novo Nordisk AS, and Pfizer Inc. Challenges include operational costs and stringent regulations.

SkyQuest projects the global healthcare analytical testing services market to reach USD 15.55 Billion by 2031, with a CAGR of 11.2% (2024-2031). Driving factors include outsourcing by pharmaceutical and medical device companies, increased clinical trials, and rising biosimilars emphasis. The COVID-19 pandemic also boosted demand.

The pharmacovigilance outsourcing market is projected to grow to $11.71 billion by 2028 at a CAGR of 17.4%, driven by drug development, regulatory requirements, and clinical trials.

The global oncology-based in-vivo CRO market was valued at USD 1.4 billion in 2024 and is expected to grow at an 8.8% CAGR from 2025 to 2034, driven by demand for immuno-oncology therapies, advancements in in-vivo models, and growing oncology drug approvals from small biotech and pharmaceutical companies. Small firms lead in oncology drug approvals, focusing on innovative treatments like CAR-T cell therapy and monoclonal antibodies. The market is segmented by service, model, end use, and region, with preclinical testing dominating. Key trends include the rise of immunotherapies, outsourcing by biotech firms, AI integration, and strategic alliances between companies and CROs.

The medical device affairs outsourcing market is projected to grow to $6.7 billion by 2028 at a CAGR of 7.1%, driven by increasing demand for medical devices, regulatory approvals, and healthcare expenditure. Key trends include digital health technologies, AI, personalized medicine, and environmental sustainability.

Mick Ryan discusses AI's role in clinical research, highlighting its efficiency in handling vast datasets and accelerating drug discovery. Despite barriers like data quality and regulatory ambiguity, AI is increasingly integrated into routine workflows. Key areas of AI effectiveness include reducing computational burdens, accelerating site start-up, and supporting real-time data monitoring. Stakeholders must focus on data quality, ethical considerations, and internal infrastructure support. Regulatory challenges include compliance with frameworks like GxP and GDPR. Looking ahead, AI is expected to deeply embed across all clinical development stages, enhancing efficiency and patient experience.